CROs Getting Govt. Support To Help Countermeasure Sponsors
This article was originally published in The Pink Sheet Daily
BARDA’s Clinical Studies Network aims to reduce the number of countermeasure development failures.
You may also be interested in...
GAIN has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.
A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.
Under a pair of agreements announced Sept. 19, the HHS unit will stockpile 60,000 doses of GSK’s inhalation anthrax treatment and will fund development of a treatment for GI acute radiation syndrome by New Jersey biotech Soligenix.